Search research articles
Contact Us
Filters
Showing results (261-270 of 314) with videos related to
Page
of 32
Sort By:
Ugeskrift for Laeger
|
October 1, 2021
[Challenges in cancer treatment for the elderly]
Marianne Ewertz, Sidse Ehmsen, Trine Lembrecht Jørgensen, et al.
Plos One
|
October 3, 2012
GAGE cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (GCL)
Morten F Gjerstorff, Heike I Rösner, Christina B Pedersen, et al.
Cancer Cell
|
December 27, 2024
Targeting P4HA1 promotes CD8<sup>+</sup> T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
Shijun Ma, Li-Teng Ong, Zemin Jiang, et al.
Molecular Oncology
|
August 2, 2014
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting
Anieta M Sieuwerts, Maria B Lyng, Marion E Meijer-van Gelder, et al.
Frontiers in Oncology
|
February 11, 2025
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Charlotte K Kindt, Sidse Ehmsen, Sofie Traynor, et al.
Molecular Oncology
|
November 4, 2014
Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability
Katrine B V Greve, Jonas N Lindgreen, Mikkel G Terp, et al.
Cancer Cell
|
February 22, 2023
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
Sidse Ehmsen, Rune M Pedersen, Line L Bang, et al.
Journal for Immunotherapy of Cancer
|
September 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
Odd L Gammelgaard, Mikkel G Terp, Christian Renn, et al.
Nature Communications
|
August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Carla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Nature Communications
|
November 19, 2020
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Yi Bao, Gokce Oguz, Wee Chyan Lee, et al.
Page
of 32
Search research articles
Search
Showing results (261-270 of 314) with videos related to
Sort By:
Page
of 32
Ugeskrift for Laeger
|
October 1, 2021
[Challenges in cancer treatment for the elderly]
Marianne Ewertz, Sidse Ehmsen, Trine Lembrecht Jørgensen, et al.
Plos One
|
October 3, 2012
GAGE cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (GCL)
Morten F Gjerstorff, Heike I Rösner, Christina B Pedersen, et al.
Cancer Cell
|
December 27, 2024
Targeting P4HA1 promotes CD8<sup>+</sup> T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
Shijun Ma, Li-Teng Ong, Zemin Jiang, et al.
Molecular Oncology
|
August 2, 2014
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting
Anieta M Sieuwerts, Maria B Lyng, Marion E Meijer-van Gelder, et al.
Frontiers in Oncology
|
February 11, 2025
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Charlotte K Kindt, Sidse Ehmsen, Sofie Traynor, et al.
Molecular Oncology
|
November 4, 2014
Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability
Katrine B V Greve, Jonas N Lindgreen, Mikkel G Terp, et al.
Cancer Cell
|
February 22, 2023
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
Sidse Ehmsen, Rune M Pedersen, Line L Bang, et al.
Journal for Immunotherapy of Cancer
|
September 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
Odd L Gammelgaard, Mikkel G Terp, Christian Renn, et al.
Nature Communications
|
August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Carla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Nature Communications
|
November 19, 2020
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Yi Bao, Gokce Oguz, Wee Chyan Lee, et al.
Page
of 32